Brooks Laboratories Limited
NSE: BROOKS BSE: BROOKS
NSE
70.97
-2.00 (-2.74%)
Prev Close
72.97
Open Price
71.89
Volume
22,309
Today Low / High
70.16 / 74.95
52 WK Low / High
58.35 / 164.02
Range
67 - 75
BSE
71.00
-2.87 (-3.89%)
Prev Close
73.87
Open Price
74.73
Volume
191
Today Low / High
71 / 74.73
52 WK Low / High
59 / 165.95
Range
67 - 75
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 70.97 (target range: 67 - 75), reflecting a change of -2 (-2.74085%). On the BSE, it is listed at 71 (target range: 67 - 75), showing a change of -2.87 (-3.8852%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
23 Feb
75.28
-3.07%
20 Feb
76.00
-2.01%
19 Feb
76.65
-1.44%
18 Feb
72.61
5.56%
17 Feb
77.00
-4.42%
16 Feb
75.75
-1.85%
13 Feb
75.88
-0.09%
12 Feb
77.00
0.45%
11 Feb
74.85
4.40%
10 Feb
69.00
7.51%
09 Feb
62.99
9.91%
06 Feb
61.94
-1.63%
05 Feb
62.55
-2.54%
04 Feb
59.02
3.83%
03 Feb
61.50
-2.65%
02 Feb
61.98
-2.89%
01 Feb
61.55
1.09%
30 Jan
62.99
-2.29%
29 Jan
65.00
-4.77%
28 Jan
62.99
2.24%
Brooks Laboratories Limited Graph
Brooks Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Brooks Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 70.97, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 71.00 | 71.71 | 64.54 - 78.88 |
| 72.42 | 57.94 - 86.90 | ||
| 73.13 | 51.19 - 95.07 | ||
| Bearish Scenario | 71.00 | 70.29 | 63.26 - 77.32 |
| 69.58 | 55.66 - 83.50 | ||
| 68.87 | 48.21 - 89.53 |
Overview of Brooks Laboratories Limited
ISIN
INE650L01011
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
71,349
Market Cap
2,149,495,387
Last Dividend
0
Official Website
IPO Date
2011-09-05
DCF Diff
184.53
DCF
-82
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 82.56 Cr | 68.63 Cr | 13.92 Cr | 0.1686 | 0.00 Cr | 0.00 Cr | 3.34 Cr | -9.97 Cr | -3.29 | 5.82 Cr | -0.1207 |
| 2024-03-31 | 79.49 Cr | 72.92 Cr | 22.51 Cr | 0.2832 | 0.00 Cr | 4.37 Cr | 1.20 Cr | -19.59 Cr | -7.65 | 4.17 Cr | -0.2465 |
| 2023-03-31 | 62.48 Cr | 50.60 Cr | 12.60 Cr | 0.2017 | 0.00 Cr | 10.09 Cr | -6.90 Cr | -20.90 Cr | -8.38 | -29.17 Cr | -0.3345 |
| 2022-03-31 | 91.18 Cr | 75.80 Cr | -7.91 Cr | -0.0868 | 0.00 Cr | 8.84 Cr | 7.74 Cr | -19.31 Cr | -7.74 | -13.45 Cr | -0.2118 |
| 2021-03-31 | 77.07 Cr | 55.24 Cr | 21.83 Cr | 0.2832 | 0.00 Cr | 6.55 Cr | -10.84 Cr | -19.38 Cr | -7.77 | 1.25 Cr | -0.2514 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.25 Cr | 123.69 Cr | 25.59 Cr | 98.1043 Cr | 7.58 Cr | 6.33 Cr | 9.20 Cr | 13.97 Cr | 0.00 Cr | 0.00 Cr | 73.69 Cr | 22.8441 Cr |
| 2024-03-31 | 0.13 Cr | 90.45 Cr | 24.86 Cr | 65.5853 Cr | 5.64 Cr | 5.52 Cr | 9.61 Cr | 13.60 Cr | 0.26 Cr | 0.00 Cr | 42.91 Cr | 23.0476 Cr |
| 2023-03-31 | 0.02 Cr | 109.60 Cr | 35.64 Cr | 73.9532 Cr | 6.51 Cr | 6.49 Cr | 11.30 Cr | 14.81 Cr | 1.14 Cr | 0.00 Cr | 64.19 Cr | 33.0213 Cr |
| 2022-03-31 | 2.61 Cr | 195.91 Cr | 61.59 Cr | 87.4901 Cr | 25.26 Cr | 22.65 Cr | 27.52 Cr | 124.49 Cr | 3.58 Cr | -5.37 Cr | 0.28 Cr | 48.8783 Cr |
| 2021-03-31 | 0.88 Cr | 162.08 Cr | 82.93 Cr | 79.1484 Cr | 31.38 Cr | 30.50 Cr | 23.60 Cr | 107.70 Cr | 14.56 Cr | 0.00 Cr | -1.24 Cr | 63.7142 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.7623 Cr | -46.0409 Cr | 44.1965 Cr | -0.0971 Cr | 0.5546 Cr | 1.2480 Cr | -1.8594 Cr | -9.9670 Cr | 1.0213 Cr | 0.0000 Cr | 0.4060 Cr |
| 2024-03-31 | -9.6806 Cr | 0.1822 Cr | 9.6007 Cr | -10.1196 Cr | 0.1023 Cr | 0.1255 Cr | -0.4390 Cr | -19.5919 Cr | -0.8703 Cr | 0.0000 Cr | 1.6923 Cr |
| 2023-03-31 | -14.4906 Cr | 0.4948 Cr | 11.4140 Cr | -14.9581 Cr | -2.5818 Cr | 0.0232 Cr | -0.4675 Cr | -35.4251 Cr | -4.0322 Cr | 0.0000 Cr | 3.2860 Cr |
| 2022-03-31 | -37.4407 Cr | -24.9086 Cr | 64.0706 Cr | -65.0530 Cr | 1.7211 Cr | 2.6050 Cr | -27.6123 Cr | -23.8977 Cr | -7.2510 Cr | 0.0000 Cr | -3.9193 Cr |
| 2021-03-31 | 4.4587 Cr | -5.1296 Cr | 1.1589 Cr | -1.1551 Cr | 0.4880 Cr | 0.8839 Cr | -5.6138 Cr | -8.9933 Cr | 4.3813 Cr | 0.0000 Cr | -9.8282 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 16.57 Cr | 13.11 Cr | 3.46 Cr | 0.2088 | 0.34 Cr | 5.50 Cr | 1.87 | 0.86 Cr | 0.3319 |
| 2025-09-30 | 23.45 Cr | 13.71 Cr | 9.74 Cr | 0.4153 | 2.13 Cr | 7.98 Cr | 2.71 | 8.65 Cr | 0.3402 |
| 2025-06-30 | 25.51 Cr | 15.89 Cr | 9.62 Cr | 0.3771 | 2.74 Cr | 9.58 Cr | 3.25 | 10.28 Cr | 0.3757 |
| 2025-03-31 | 23.32 Cr | 19.58 Cr | 3.74 Cr | 0.1602 | 1.15 Cr | -1.46 Cr | -0.48 | 2.16 Cr | -0.0625 |
| 2024-12-31 | 38.45 Cr | 25.06 Cr | 13.38 Cr | 0.3481 | 1.07 Cr | -4.57 Cr | -1.51 | -3.32 Cr | -0.1189 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.03 Cr | 1.77 Cr | 1.80 Cr | 25.20 Cr | 7.74 Cr | 37.62 Cr | 14.20 Cr | 139.95 Cr | 24.28 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -98.10 Cr |
| 2025-03-31 | 1.25 Cr | 0.00 Cr | 1.25 Cr | 19.99 Cr | 9.20 Cr | 33.88 Cr | 13.97 Cr | 123.69 Cr | 25.59 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -59.21 Cr |
| 2024-09-30 | 0.17 Cr | 2.18 Cr | 2.35 Cr | 23.70 Cr | 9.48 Cr | 37.86 Cr | 14.55 Cr | 91.12 Cr | 31.92 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 9.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -1.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -4.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -3.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -2.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-02-11 | February 11, 20 | 1199:1000 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,731.80 | ₹4,155,168,301,046.00 | ₹2,769,336.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,255.50 | ₹1,660,638,702,190.00 | ₹92,138.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,397.90 | ₹1,488,449,200,576.00 | ₹846,302.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,300.20 | ₹1,082,505,160,638.00 | ₹1,802,879.00 |
| Lupin Limited | LUPIN | ₹2,250.20 | ₹1,028,438,158,600.00 | ₹1,065,762.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹903.85 | ₹909,484,591,862.00 | ₹368,888.00 |
| Mankind Pharma Limited | MANKIND | ₹2,054.70 | ₹848,190,581,438.00 | ₹217,516.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,164.40 | ₹676,285,409,821.00 | ₹987,804.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,495.50 | ₹657,069,457,500.00 | ₹119,453.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,058.60 | ₹580,938,585,407.00 | ₹372,421.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,028.50 | ₹555,242,494,587.00 | ₹1,411,584.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,515.30 | ₹384,438,001,535.00 | ₹150,378.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,948.80 | ₹368,410,168,051.00 | ₹55,209.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,070.40 | ₹332,356,231,238.00 | ₹674,051.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,434.50 | ₹271,941,808,630.00 | ₹126,588.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,362.00 | ₹221,314,334,178.00 | ₹244,316.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,800.50 | ₹220,012,500,000.00 | ₹5,234.00 |
| Eris Lifesciences Limited | ERIS | ₹1,384.60 | ₹188,605,907,279.00 | ₹127,178.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,366.00 | ₹171,484,296,374.00 | ₹45,522.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹944.85 | ₹169,231,960,670.00 | ₹10,306,610.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹750.85 | ₹147,589,421,655.00 | ₹66,813.00 |
| Granules India Limited | GRANULES | ₹599.60 | ₹145,504,162,114.00 | ₹532,194.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹879.00 | ₹139,207,008,492.00 | ₹173,438.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,712.60 | ₹130,177,630,570.00 | ₹59,587.00 |
| Cohance Lifesciences Limited | COHANCE | ₹309.55 | ₹118,423,658,187.00 | ₹803,652.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹883.60 | ₹108,449,529,600.00 | ₹60,419.00 |
| Viyash Scientific Limited | VIYASH | ₹219.42 | ₹95,712,223,756.00 | ₹660,093.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,161.00 | ₹85,669,410,502.00 | ₹15,824.00 |
| Strides Pharma Science Limited | STAR | ₹861.00 | ₹79,360,706,754.00 | ₹126,250.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹483.70 | ₹74,055,465,455.00 | ₹170,943.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹320.55 | ₹62,693,751,119.00 | ₹180,158.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹690.90 | ₹62,628,212,661.00 | ₹146,064.00 |
| FDC Limited | FDC | ₹368.85 | ₹60,052,499,483.00 | ₹76,713.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹127.50 | ₹41,376,502,470.00 | ₹473,000.00 |
| Innova Captab Limited | INNOVACAP | ₹671.80 | ₹38,443,707,302.00 | ₹18,427.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹319.30 | ₹34,792,609,115.00 | ₹45,187.00 |
| Suven Life Sciences Limited | SUVEN | ₹148.96 | ₹33,884,527,040.00 | ₹164,413.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹369.50 | ₹33,724,265,000.00 | ₹71,369.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹647.90 | ₹32,860,908,130.00 | ₹51,609.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,882.30 | ₹31,131,387,935.00 | ₹7,493.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹281.10 | ₹28,189,412,437.00 | ₹74,640.00 |
Key Executives
Vice President of Sales & Marketing
Nikhil Anand Verma
Gender: Not Specified
Year Born: 1964
Whole-Time Director
Durga Shankar Maity
Gender: Not Specified
Year Born: 1964
Whole-Time Director
Bhushan Singh Rana
Gender: male
Year Born: 1955
Whole-Time Director
Jitendra Pratap Singh
Gender: male
Year Born: 1973
President of Corporate Strategy
Atul Ranchal
Gender: male
Year Born: 1967
Chief Financial Officer
Prashant Rathi
Gender: male
Year Born: 1991
Company Secretary & Compliance Officer
Krutika Mohan Rane
Gender: female
Year Born: 1993
FAQs about Brooks Laboratories Limited
Who is the CEO of the company?
The CEO is Prashant Rathi.
What is the current market price of the stock?
The current price is ₹72.97.
What is the 52-week price range?
The range is ₹58.35-164.02.
What is the market capitalization of the company?
The market capitalization is ₹214.95 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 9.93.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Brooks Laboratories Limited (ISIN: INE650L01011) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹214.95 crores and an average daily volume of 71,349 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.